Warren Morgan, MD
Otolaryngology · Cypress, TXNPI 1295721652
Payments from drug & device makers
Across 82 payments — averaging $57.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$983
- Medtronic$523
- Intersect ENT, Inc.$510
- Optinose US, Inc.$485
- Neurent Medical Limited$450
- Inspire Medical Systems, Inc.$339
- plus $1K from 11 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$4,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 14 | $983 |
| Medtronic(2 entities) | 9 | $523 |
| Intersect ENT, Inc. | 6 | $510 |
| Optinose US, Inc. | 11 | $485 |
| Neurent Medical Limited | 9 | $450 |
| Inspire Medical Systems, Inc. | 5 | $339 |
| Acclarent, Inc | 7 | $335 |
| Aerin Medical Inc. | 4 | $307 |
| Integra Lifesciences Corporation | 2 | $164 |
| Johnson & Johnson | 2 | $156 |
| GSK | 3 | $125 |
| Olympus America Inc. | 2 | $116 |
| Sanofi | 1 | $92 |
| Regeneron Healthcare Solutions, Inc. | 2 | $61 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $46 |
| Hikma Pharmaceuticals USA | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$352
- NEUROMARK System$277
- NEUROMARK Radiofrequency Console$277
- ENTELLUS - XPRESS ENT DILATION SYSTEM$259
- SINUVA$246
- XPRESS ENT DILATION SYSTEM$230
- AUDION ET DILATION SYSTEM$149
- VIVAER STYLUS$145
- RHINAER STYLUS$145
- Xhance$145
- Inspire$141
- Acclarent Aera$137
- Inspira Air$137
- RELIEVA SPINPLUS NAV$137
- TruDi Probe$137
- TruDi Nav Cable$123
- Relieva Spinplus$123
- FUSION$119
- Inspire Upper Airway Stimulation System$118
- Vivaer RF Stylus$109
How this compares
$4,752 in reported general payments places this provider in the 70th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 11 | $7,866 |
| Azelastine Hcl | 141 | $4,529 |
| Fluticasone Propionate | 334 | $4,446 |
| Ipratropium Bromide | 114 | $2,989 |
| Cefdinir | 122 | $2,781 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 16 | $1,881 |
| Epinephrine | 12 | $1,769 |
| Ofloxacin | 100 | $1,451 |
| Betamethasone Dipropionate | 23 | $686 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 50 | $559 |
| Omeprazole | 51 | $548 |
| Famotidine | 26 | $421 |
| Clindamycin Hcl | 35 | $410 |
| Methylprednisolone | 46 | $297 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $485 | $7,86611 claims |
| Hikma Pharmaceuticals USAEpinephrine | $44 | $1,76912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Cypress
- Laurence ChuAustin$37.4M
- Mark ZafereoHouston$7.8M
- Neil GrossHouston$1.5M
- Chad McDuffieFrisco$1.5M
- Ian AlexanderBoerne$999K
- Stephen LaiHouston$968K
- Benjamin CilentoSpring$963K
- Amber LuongHouston$793K
- Jeffrey RosenbloomSan Antonio$720K
- Masayoshi TakashimaHouston$644K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.